These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35746485)

  • 1. Surveillance of Adverse Events Following Immunization (AEFI) after Third Dose Booster Vaccination with mRNA-Based Vaccine in Universitas Indonesia Hospital Health Personnel.
    Hidayat R; Mustika AP; Avisha F; Djuliannisaa Z; Winari DD; Putri RA; Lisman HM; Davin V; Widhani A; Aini MH; Rahmadani M; Istanti ND; Giantini A
    Vaccines (Basel); 2022 May; 10(6):. PubMed ID: 35746485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 Vaccines Programs: adverse events following immunization (AEFI) among medical Clerkship Student in Jember, Indonesia.
    Supangat ; Sakinah EN; Nugraha MY; Qodar TS; Mulyono BW; Tohari AI
    BMC Pharmacol Toxicol; 2021 Oct; 22(1):58. PubMed ID: 34641944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse events following immunisation of COVID-19 vaccine among health care workers in the first phase of vaccination.
    Rahmat H; Leelavathi M; Wan Ismail WF
    Med J Malaysia; 2022 Nov; 77(6):637-642. PubMed ID: 36448378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of Adverse Events Experienced by Healthcare Workers following Immunization with Homologous orHeterologous COVID-19 Booster Vaccinations.
    Wei Y; Wang Y; Liu J; Zha Y; Yang Y; Li N; Zhou Y; Roberts JZN; Liu L; Li Y
    Vaccines (Basel); 2022 Nov; 10(11):. PubMed ID: 36366377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of Repeated Adverse Effects following Booster Dose of mRNA COVID-19 Vaccine: Results from the MOSAICO Study.
    Ferrara P; Ponticelli D; Losa L; Romeo C; Magliuolo R; Vitale A; Zampella A; Alleanza L; Borrelli M; Schiavone B; Mantovani LG
    Vaccines (Basel); 2023 Jan; 11(2):. PubMed ID: 36851125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse events following immunization of COVID-19 vaccine among children aged 6-11 years.
    Puspitarani F; Sitaresmi MN; Ahmad RA
    Front Public Health; 2022; 10():999354. PubMed ID: 36388348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors influencing adverse events following immunization with AZD1222 in Vietnamese adults during first half of 2021.
    Tran VN; Nguyen HA; Le TTA; Truong TT; Nguyen PT; Nguyen TTH
    Vaccine; 2021 Oct; 39(44):6485-6491. PubMed ID: 34607748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse events following immunization (AEFI): COVID-19 vaccine dose and characteristics in Central Java, Indonesia.
    Wahyudi F; Nugraheni A; Margawati A; Pramono D; Adespin DA; Nugroho TW; Pramana C
    Germs; 2023 Mar; 13(1):40-49. PubMed ID: 38023961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active surveillance of adverse events following immunization (AEFI): a prospective 3-year vaccine safety study.
    Sebastian J; Gurumurthy P; Ravi MD; Ramesh M
    Ther Adv Vaccines Immunother; 2019; 7():2515135519889000. PubMed ID: 31799496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Willingness to receive a vaccine is influenced by adverse events following immunisation experienced by others.
    Christou-Ergos M; Wiley KE; Leask J
    Vaccine; 2023 Jan; 41(1):246-250. PubMed ID: 36446655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active SMS-based surveillance of adverse events following immunisation with influenza and pertussis-containing vaccines in Australian pregnant women using AusVaxSafety.
    Glover C; Crawford N; Leeb A; Wood N; Macartney K
    Vaccine; 2020 Jun; 38(31):4892-4900. PubMed ID: 32499067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Cross-Sectional Study to Assess mRNA-COVID-19 Vaccine Safety among Indian Children (5-17 Years) Living in Saudi Arabia.
    Ahsan M; Shaik RA; Mallick AK; Banawas SS; Alruwaili TAM; Alanazi YA; Alzahrani HS; Ahmad RK; Ahmad MS; AlAnazi FH; Alfhaid F; Aljulifi MZ; Mehta V; Almhmd AE; Daham ASDA; Alruwaili MMM
    Vaccines (Basel); 2023 Jan; 11(2):. PubMed ID: 36851085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse Events Following COVID-19 Vaccination in Selected Apartments in Bangalore, India.
    Chakraborty A; Reval N; Kamath L
    Cureus; 2022 Feb; 14(2):e21809. PubMed ID: 35291520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 vaccination: Is it a matter of concern?
    Kushwaha P; Pundhir A; Gahlot A
    J Family Med Prim Care; 2022 Jun; 11(6):2431-2436. PubMed ID: 36119229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of Adverse Events Following COVID-19 Vaccination: A Cross-sectional Study in Ibadan, Nigeria.
    Alao MA; Ogunbosi BO; Ibrahim OR; Oladokun RE; Lagunju IA
    Niger Med J; 2022; 63(3):248-258. PubMed ID: 38835530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine.
    Spinelli FR; Favalli EG; Garufi C; Cornalba M; Colafrancesco S; Conti F; Caporali R
    Arthritis Res Ther; 2022 Jan; 24(1):21. PubMed ID: 35016701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine Safety: Assessing the Prevalence and Severity of Adverse Events Following COVID-19 Vaccination amongst Healthcare Workers in Tertiary Health Facilities in Nigeria.
    Azees AS; Fasiku MM; Isa A; Ezenwoko AZ; Ahmed A; Temitayo-Oboh AO; Utulu R; Adeniyi MA; Musa A; Alo C; Ibrahim UM; Imhonopi GB; Adesoye OO; Okeke IM; John GT; Ayinla AY
    Niger Postgrad Med J; 2024 Jan; 31(1):1-7. PubMed ID: 38321791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse events following immunization: Findings from 2017/2018 measles vaccination campaign, Nigeria AEFI reporting in 2017/2018 measles vaccination campaign.
    Gbenewei E; Nomhwange T; Taiwo L; Ayodeji I; Yusuf K; Jean Baptiste AE; Nsubuga P; Braka F; Oteri J; Shuaib F
    Vaccine; 2021 Nov; 39 Suppl 3():C82-C88. PubMed ID: 33714655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence, Pattern and Severity of Adverse Events Following Immunization (AEFIs) Associated With Chadox1 nCOV-19 Corona Virus Vaccine (Recombinant) Among the Healthcare Workers of a Tertiary Care Institute of Eastern Uttar Pradesh, India.
    Kamble B; Bashar MA; Mishra CP
    Cureus; 2022 Feb; 14(2):e21848. PubMed ID: 35273834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety profile of inactivated COVID-19 in healthy adults aged ≥ 18 years: A passive surveillance in Indonesia.
    Kaswandani N; Medise BE; Leonard E; Satari HI; Sundoro J; Hadinegoro SRH; Putra A; Angkasa PF
    PLoS One; 2023; 18(10):e0286484. PubMed ID: 37824453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.